INSTAPRIN ACQUISITION (Details Narrative) - Aspire Biopharma Inc [Member] - USD ($) |
Mar. 28, 2022 |
Dec. 31, 2024 |
|---|---|---|
| Restructuring Cost and Reserve [Line Items] | ||
| Transaction costs | $ 316,800,000 | |
| Instaprin Pharmaceuticals Inc [Member] | ||
| Restructuring Cost and Reserve [Line Items] | ||
| Assets acquired | $ 3,628,325 | |
| Business acquistion percentage | 20.00% | |
| Transaction costs | $ 5,000,000 | |
| Business acquistion description | 10% from sales thereafter until the entire contingent purchase price obligation is satisfied. Additionally, ten percent (10%) of Buyer’s equity was to be delivered at Closing, in proportion to their equity holdings in the Company, to be issued to a Trustee for the former Instaprin Shareholders, along with an additional ten percent (10%) of Buyer’s equity to be issued to the Company’s service providers, pursuant to a stock incentive plan to be adopted. |